- Home
- SGA vs SERA Comparison
SGA vs SERA Comparison
Compare SGA & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGA | SERA |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 79.5M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SGA | SERA |
|---|---|---|
| Price | $11.97 | $1.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.8K | ★ 91.5K |
| Earning Date | 03-12-2026 | 03-18-2026 |
| Dividend Yield | ★ 8.33% | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $124,829,000.00 | $81,000.00 |
| Revenue This Year | $6.74 | $875.93 |
| Revenue Next Year | N/A | $248.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.65 | 5.19 |
| 52 Week Low | $10.68 | $1.37 |
| 52 Week High | $14.27 | $4.09 |
Technical Indicators
Market Signals| Indicator | SGA | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 57.05 | 37.22 |
| Support Level | $11.75 | $1.72 |
| Resistance Level | $11.99 | $2.00 |
| Average True Range (ATR) | 0.31 | 0.22 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 85.22 | 24.69 |
Price Performance
Historical ComparisonAbout SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.